Know the difference, make a difference

for women with aortic stenosis.†


Give your patients with symptomatic severe aortic stenosis (ssAS) the valve performance advantages of Medtronic Evolut™ TAVR.1


Exclamation icon Indications, Safety, and Warnings
TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.

Timely treatment is critical for survival.


Failure to seek timely treatment for ssAS is a problem that can cost patients their lives. If left untreated, average patient survival is just 50% at two years.2


Once symptoms begin, survival is cut short2


Treating aortic stenosis graphic

Detecting aortic stenosis in women can be more challenging.


Diagnosing ssAS can be more challenging in women compared to men, because their symptoms appear differently, and the severity is more frequently underestimated.3,4 Review the common diagnostic challenges and see what you can do to provide more effective treatment of ssAS.


Diagnostic challenges
Older couple on a bench seat Women with ssAS face a higher risk of mortality than men at the same age.
Woman are up to
less likely to be treated for TAVR or SAVR.7

Help close the treatment gap for women with aortic stenosis.


When it comes to heart valve disease, research shows that aortic stenosis (AS) impacts women differently than men, which must be addressed to ensure timely treatment and save lives.6

Smart trial logo

The SMART Trial makes a difference.


The SMART Trial is the largest, most rigorous trial to date, to randomize patients to the two most widely used TAVR devices, and the largest TAVR trial to enroll predominantly women.8


Not all TAVRs are the same.



The SMART Trial enrolled 87% women8

SMART Trial findings


When TAVR is the best option, it can make a difference in overall health outcomes. Based on the initial SMART results, the data points to Evolut™ TAVR — proven for women.‡,8

Evolut™ TAVR delivers superior valve performance§ in women with a small annulus at one year versus SAPIEN™ platform.8
BVD in women vs. SAPIEN™ platform bar graph
5x less

BVD in women

vs. SAPIEN™ platform at
one year p < 0.001.8


‡ Based on the 1 year follow-up results from the SMART clinical trial which showed differences in valve performance for Evolut compared to SAPIEN and no differences in safety outcomes. SMART primarily studied small annulus patients, predominantly women.8

TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.

Evolut™ TAVR Valve Performance

Performance matters


Sustained valve performance, as defined as freedom from bioprosthetic valve dysfunction (BVD), helps keep your patients alive and out of the hospital.9

If women do receive TAVR treatment, they have superior valve performance compared to the SAPIEN™ platform at 1 year, based on results from the SMART trial.8


Learn more about valve performance Arrow icon

TAV

Evolut™ TAVR has a differentiated design that matters for your patient.


Built on the original CoreValve platform, Evolut™ FX+ is engineered with specific design elements to promote sustained valve performance with consistently large EOAs and low gradients over time.11


Durability starts with design.

1Supra annular positioning

2Nitinol frame

3External tissue wrap

4Four-times larger windows

Evolut™ TAVR differentiated design that matters for your patient

You’ve chosen TAVR, now choose Evolut™

Valve performance§ matters from day one.
Evolut™ TAVR delivers superior valve performance§ in women with small annuli at 1 year vs. SAPIEN platform.8
Valve selection matters. Evolut™ TAVR – proven for women.‡,8

‡ Based on the 1 year follow-up results from the SMART clinical trial which showed differences in valve performance for Evolut compared to SAPIEN and no differences in safety outcomes. SMART primarily studied small annulus patients, predominantly women.8

TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.

Valve performance starts the day of the procedure and continues for a lifetime.

Give your patients a proven treatment option to treat ssAS. When you believe TAVR is the best treatment for your patients, you may not be thinking of a particular valve. Maybe you should be.


Explore durability

Valve performance

Find a Heart Team with Evolut™ experience.

Heart icon

Finding the right Heart Team can make a difference.


Compared to the SAPIEN™ TAVR valve, Evolut™ TAVR demonstrated significantly better VARC-3 ordinal outcomes for quality of life at 12 months.8 Give your TAVR patients, especially women, the chance to benefit from a Heart Team experienced with Evolut™.


Find an Evolut™ Experienced Heart Team

Additional resources.

Email icon

Stay in the know!


Stay updated on the latest TAVR clinical evidence, educational event offerings, and local and national congress events by signing up for Medtronic TAVR communications.


Sign up Arrow icon

Resources icon

Patient Education Resources


Provide your patients with educational resources that will help them better understand their ssAS and TAVR as a potential treatment option.


Download TAVR Discussion Guide Arrow icon

Download Medtronic TAVR patient brochure Arrow icon

TAVRforWomen.com Arrow icon

TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.

™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

† Evolut TAVR is indicated to treat patients who have been diagnosed with symptomatic severe aortic stenosis.

‡ Based on the 1 year follow-up results from the SMART clinical trial which showed differences in valve performance for Evolut compared to SAPIEN and no differences in safety outcomes. SMART primarily studied small annulus patients, predominantly women.8

§ Better blood flow, or "near-normal transvalvular flow" means that your new heart is operating well and the gradient across your valve is < 20 mmHg%


  1. Herrmann HC, Mehran R, Blackman DJ, et al. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med. June 6 2024;390(21):1959–1971
  2. Ross J Jr, Braunwald E. Aortic stenosis. Circulation. July 1968;38(1 Suppl):61-67. 
  3. Nau DP , Ellis JJ , Kline-Rogers EM, Mallya U, Eagle KA, Erickson SR. Gender and perceived severity of cardiac disease: evidence that women are “tougher.” Am J Med. November 2005;118(11):1256–1261.
  4. Iribarren AC, AlBadri A, Wei J, et al. Sex differences in aortic stenosis: Identification of knowledge gaps for sex-specific personalized medicine. Am Heart J Plus. September 2022;21:100197. 
  5. Tribouilloy C, Bohbot Y, Rusinaru D, et al. Excess Mortality and Undertreatment of Women With Severe Aortic Stenosis. J Am Heart Assoc. January 5, 2021;10(1):e018816 
  6. Julia Stehli, Rozanne Johnston, Stephen J Duffy, Sarah Zaman, Tomoe D H Gusberti, Misha Dagan, Dion Stub, Antony Walton, Waiting times of women vs. men undergoing transcatheter aortic valve implantation, European Heart Journal - Quality of Care and Clinical Outcomes, Volume 9, Issue 7, November 2023, Pages 691–698.
  7. Rice CT, Barnett S, O’Connell SP, et al. Impact of gender, ethnicity and social deprivation on access to surgical or transcatheter aortic valve replacement in aortic stenosis: a retrospective database study in England. Open Heart. September 2023;10(2):e002373.
  8. Tchétché D, Mehran R, Blackman DJ, et al. Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial. JAMA Cardiol. Published online October 9, 2024.
  9. Yakubov SJ, Van Mieghem NM, Oh JK, Ito S, Grubb KJ, O’Hair D, Forrest JK, Gada H, Mumtaz M, Deeb GM, Tang GHL, Rovin JD, Jain R, Windecker S, Skelding KA, Kleiman NS, Chetcuti SJ, Dedrick A, Boatman SV, Popma JJ, Reardon MJ, Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk, Journal of the American College of Cardiology (2025), doi: https://doi.org/10.1016/j.jacc.2025.02.009.
  10. Reardon M, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Aortic Stenosis Patients at Low Surgical Risk: 4-Year Outcomes from the Evolut Low Risk Trial. Presented at TCT; October 2023.
  11. Medtronic computational data model on file compared to the Evolut platform. Bench top computational model may not be indicative of clinical performance. Evolut FX+ Test Report: DO1106198 Rev. A.
  12. Adams DH, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prothesis. N Engl J Med. 2014;370:1790-1798
  13. STS Adult Cardiac Database. 2010 Harvest, Isolated AVR.
  14. Bach DS, Cimino N, Deeb GM. Unoperated patients with severe aortic stenosis. J Am Coll Cardiol. 2007 Nov 13;50(20):2018-9. doi: 10.1016/j.jacc.2007.08.011. Epub 2007 Oct 29. PMID: 17996571.
  15. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, Barnes ME, Tajik AJ. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation. 2005 Jun 21;111(24):3290-5. doi: 10.1161/CIRCULATIONAHA.104.495903. Epub 2005 Jun 13. PMID: 15956131.
  16. Charlson E, Legedza AT, Hamel MB. Decision-making and outcomes in severe symptomatic aortic stenosis. J Heart Valve Dis. 2006 May;15(3):312-21. PMID: 16784066.
  17. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006 Sep 16;368(9540):1005-11. doi: 10.1016/S0140-6736(06)69208-8. PMID: 16980116.
  18. Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993 Apr;21(5):1220-5. doi: 10.1016/0735-1097(93)90249-z. PMID: 8459080.
  19. Mack MJ, Brennan JM, Brindis R, et al. Outcomes Following Transcatheter Aortic Valve Replacement in the United States. JAMA. 2013;310(19):2069–2077. doi:10.1001/jama.2013.282043
  20. Medtronic data on file.
  21. Lung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003 Jul;24(13):1231-43. doi: 10.1016/s0195-668x(03)00201-x. PMID: 12831818.
  22. Bavaria JE. TAVR Update: New Insights and Perspectives from the U.S. National STS/ACC TVT Registry. Available from STS National Database.
  23. McCarthy CP, et al. Cleve Clin J Med. 2016;83:271-280
  24. Brennan J, Leon MB, Sheridan P, Boero IJ, Chen Q, Lowenstern A, Thourani V, Vemulapalli S, Thomas K, Wang TY, Peterson ED. Racial Differences in the Use of Aortic Valve Replacement for Treatment of Symptomatic Severe Aortic Valve Stenosis in the Transcatheter Aortic Valve Replacement Era. J Am Heart Assoc. 2020 Aug 18;9(16):e015879. doi: 10.1161/JAHA.119.015879. Epub 2020 Aug 11. PMID: 32777969; PMCID: PMC7660794.
  25. Wijeysundera HC, et al. Impact of wait times on the effectiveness of transcatheter aortic valve replacement in severe aortic valve disease: a discrete event simulation model Can J Cardiol. 2014;30:1162–1169.
  26. Medtronic internal data on file.
  27. Kornyeva A, Burri M, Lange R, Ruge H. Self-expanding vs. balloon-expandable transcatheter heart valves in small aortic annuli. Front Cardiovasc Med. August 3, 2023;10:1175246.
  28. Forrest JK, Deeb GM, Yakubov SJ, et al. 4-Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial. JACC. October 24, 2023;S0735–1097(23):07628–07633. 
  29. Stanova V, Rieu R, Thollon L, et al. Leaflet Mechanical Stress in Different Designs and Generations of Transcatheter Aortic Valves: An In Vitro Study. Struct Heart. December 19, 2023;8(2):100262.